<DOC>
	<DOCNO>NCT01298882</DOCNO>
	<brief_summary>Aim . To assess effect interleukin 1β ( IL-1β ) tumor necrosis factor α ( TNFα ) inhibition diacerein administration insulin secretion metabolic control drug-naïve patient type 2 diabetes mellitus ( T2DM ) overweight obesity . Hypothesis . Diacerein administration improve insulin secretion metabolic control drug-naïve patient type 2 diabetes mellitus ( T2DM ) overweight obesity . Materials method . Design : Randomized , double-blind , placebo-controlled clinical trial . Population : 40 drug-naïve adult patient T2DM overweight obesity . Measurements : A metabolic profile include IL-1β , TNFα , interleukin 6 , fast insulin level , well , hyperglycemic-hyperinsulinemic clamp technique ; assess phase insulin secretion insulin sensitivity . Intervention 2 mo : diacerein ( 50 mg daily ) first 15 day twice daily 45 additional day placebo . Statistical analysis : Wilcoxon sign rank Mann-Whitney U test .</brief_summary>
	<brief_title>Diacerein Insulin Secretion Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Diacetylrhein</mesh_term>
	<criteria>Fasting glucose level 7.0 11.1 mmol/L A1C level 7 9 % Same residential area socioeconomic status Excessively sedentary participate heavy physical activity Nonsmokers Body weight stable least 3 month study Blood pressure &lt; 130/80 mm Hg Personal history hepatic , renal coronary artery disease Medications know affect metabolism previous 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Overweight</keyword>
	<keyword>Obesity</keyword>
</DOC>